NNNN (Anbio Biotechnology) Cyclically Adjusted PS Ratio: (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NNNN Anbio Biotechnology NNNN
24 GF Score
Price $9.53
! 2 Warning Signs
View Full Analysis

What is Anbio Biotechnology Cyclically Adjusted PS Ratio?

Anbio Biotechnology does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Anbio Biotechnology  (NAS:NNNN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Anbio Biotechnology Cyclically Adjusted PS Ratio Related Terms


Anbio Biotechnology Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Anbio Biotechnology's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anbio Biotechnology Cyclically Adjusted PS Ratio Chart

Anbio Biotechnology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
0.00 0.00 0.00 0.00 0.00

Anbio Biotechnology Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

NNNN vs ANGO, OSUR, UTMD: Cyclically Adjusted PS Ratio Comparison

For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anbio Biotechnology Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Anbio Biotechnology's Cyclically Adjusted PS Ratio falls into.


NNNN
24GF Score
Anbio Biotechnology NNNN
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anbio Biotechnology Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Anbio Biotechnology does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.


Anbio Biotechnology Business Description

Address Friedrich-Ebert-Anlage 35-37, Frankfurt am Main, HE, DEU, 60327
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score

Get the complete analysis for NNNN

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.53
Price